首页> 外文OA文献 >Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naiuml;ve and experienced HIV-positive patients

【2h】

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naiuml;ve and experienced HIV-positive patients

机译：与RARTEGRAVIR加上骨架，Darunavir + Ritonavir Plus骨架和efavirenz / Tenofovir / Emtrickabine治疗幼稚症和经验丰富的艾滋病毒阳性患者的成本效果分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Umberto Restelli; Giuliano Rizzardini; Andrea Antinori; Adriano Lazzarin; Marzia Bonfanti; Paolo Bonfanti; Davide Croce;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment na?ve and experienced HIV-positive patients [J] . Umberto Restelli, Giuliano Rizzardini, Andrea Antinori, Therapeutics and Clinical Risk Management . 2017,第2期

机译：在未接受过治疗和有经验的HIV阳性患者中比较dolutegravir加主治与raltegravir加主治，darunavir + ritonavir加主治和依非韦伦/替诺福韦/恩曲他滨比较的成本效益分析
2. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial [J] . Post Frank A., Yazdanpanah Yazdan, Schembri Gabriel, HIV clinical trials . 2017,第3期

机译：Emtricicabine / Tenofovir Alafenaine（FTC / TAF）与Emtrickabine / Tenofovir Disoproxil umarate（FTC / TDF）作为用于治疗病毒学抑制成人的HIV-1感染的骨干的疗效和安全性：由随机的第三代理分析亚组分析 -blind，主动控制的第3阶段试验
3. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone [J] . José A. Mira12? Luis F. López-Cortés3? Pablo Barreiro4 Cristina Tural5 Manuel Torres-Tortosa6? Ignacio de los Santos Gil7 Patricia Martín-Rico8? María J. Ríos-Villegas9? José Juan Hernández-Burruezo10? Dolores Merino11? Miguel ángel López-Ruz12? Antonio Rivero13? Leopoldo Mu?oz14? Mercedes González-Serrano15? Antonio Collado16? Juan Macías12? Pompeyo Viciana3? Vincent Soriano4 and Juan A. Pineda1? Journal of Antimicrobial Chemotherapy . 2008,第6期

机译：聚乙二醇干扰素联合病毒唑治疗丙型肝炎/丙型肝炎病毒合并感染患者接受阿巴卡韦加拉米夫定或替诺福韦加拉米夫定或恩曲他滨作为核苷类似物骨架的疗效
4. Efficacy and Safety of Didanosine (ddI) and Tenofovir (TDF) Combination as NRTI Backbone of Highly Active Antiretrovirai Treatment (HAART). (24 wk Preliminary Results from Recover Study). [C] . M.J. Galindo, J. Lopez Aldeguer, M. Salavert International AIDS Conference . 2004

机译：脱蛋白（DDI）和替诺福韦（TDF）组合作为高活性抗逆转录（HAART）的NRTI骨架的疗效和安全性。（恢复研究中的24条WK初步结果）。
5. Cost effectiveness analysis of abacavir/lamivudine versus tenofovir/emtricitabine combination therapy as part of highly active antiretroviral therapy in treatment naive HIV-infected patients. [D] . Giguere, Pierre. 2010

机译：阿巴卡韦/拉米夫定与替诺福韦/恩曲他滨联合疗法作为高活性抗逆转录病毒疗法治疗未受HIV感染的患者的成本效益分析。
6. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients [O] . Umberto Restelli, Giuliano Rizzardini, Andrea Antinori, 2017

机译：在未接受过治疗和有经验的HIV阳性患者中比较dolutegravir加主治与raltegravir加主治darunavir + ritonavir加主治和依非韦伦/替诺福韦/恩曲他滨比较的成本效益分析
7. Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial [O] . Frank A. Post, Yazdan Yazdanpanah, Gabriel Schembri, 2017

机译：Emtricicabine / Tenofovir Alafenainide（FTC / TAF）与Emtricicabine / Tenofovir Disoproxil（FTC / TDF）作为治疗病毒学抑制成人HIV-1感染的骨干（FTC / TDF）的疗效和安全性：由随机的第三种试剂分析亚组分析-blind，主动控制的第3阶段试验

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naiuml;ve and experienced HIV-positive patients

著录项

引文网络

相似文献

相关主题

期刊订阅